Biomarker for microdomain disease
AssigneeSumitomo Chemical Company, Limited
InventorsKiyoshi Higashi, Toshiyuki Mikami
Life of this patent
Estimating the term…
Abstract
The present invention relates to a diagnostic technique related to a biomarker for a microdomain disease and a method for detecting a microdomain disease of which manipulation is easy and which is inexpensive.
Claims18
A method for detecting a microdomain disease in a test animal comprising a step of measuring the amount or activity of GM2A in a biological sample obtained from the test animal and a step of comparing the measured amount or activity of GM2A with a threshold.
A method for monitoring change in a disease state of a microdomain disease comprising a step of measuring the amount or activity of GM2A in a biological sample obtained from a test animal and a step of comparing the measured amount or activity of GM2A with the amount or activity of GM2A. measured for the test animal at differing time points.
Use of GM2A as a biomarker for a microdomain disease.
A kit for diagnosis of a microdomain disease which comprises a reagent for measuring the amount or activity of GM2A.
A nonhuman transgenic animal into which a gene modified so that the expression level of GM2A can increase has been introduced.
A nonhuman animal to which GM2A protein has been administered to artificially increase the amount or activity of GM2A in blood.
A prophylactic or therapeutic agent for a microdomain disease which comprises an anti-GM2A antibody as an active ingredient.
A prophylactic or therapeutic agent for a microdomain disease which comprises a GM2A-inhibitory active compound as an active ingredient.
Dependencies are inferred from the claim text.